Targeting for cardioplegia: arresting agents and their safety

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 220-226

  Fallouh, Hazem B ^a   Kentish, Jonathan C ^b   Chambers, David J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CALCIUM CHANNEL L TYPE; CALCIUM ION; CARDIOPLEGIC AGENT; DIACETYL OXIME; DILTIAZEM; ESMOLOL; LIDOCAINE; MAGNESIUM; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHLORIDE; SODIUM CHANNEL; TETRODOTOXIN; VERAPAMIL;

CARDIOPLEGIA; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; LOW DRUG DOSE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNEL BLOCKERS; CARDIOPLEGIC SOLUTIONS; DRUG DELIVERY SYSTEMS; HEART ARREST, INDUCED; HUMANS; POTASSIUM CHANNELS; PROPANOLAMINES;

EID: 62349141161     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.11.012     Document Type: Review

References (68)

1. Lewis F.J., and Taufic M. Closure of atrial septal defects with the aid of hypothermia; experimental accomplishments and the report of one successful case. Surgery 33 (1953) 52-59
2. Katz A.M., and Tada M. The 'stone heart': a challenge to the biochemist. Am J Cardiol 29 (1972) 578-580
3. Hutchins G.M., and Silverman K.J. Pathology of the stone heart syndrome. Massive myocardial contraction band necrosis and widely patent coronary arteries. Am J Pathol 95 (1979) 745-752
4. + as a concept of mechanical arrest.
5. Lam C.R., Gahagan T., Sergeant C., and Green E. Clinical experiences with induced cardiac arrest during intracardiac surgical procedures. Ann Surg 146 (1957) 439-449
6. Hearse D.J., Stewart D.A., and Braimbridge M.V. Hypothermic arrest and potassium arrest: metabolic and myocardial protection during elective cardiac arrest. Circ Res 36 (1975) 481-489. First paper of many others towards the development of STH.
7. McAllister R.E., Noble D., and Tsien R.W. Reconstruction of the electrical activity of cardiac Purkinje fibres. J Physiol 251 (1975) 1-59
8. Attwell D., Cohen I., Eisner D., Ohba M., and Ojeda C. The steady state TTX-sensitive ('window') sodium current in cardiac Purkinje fibres. Pflugers Arch 379 (1979) 137-142
9. Pike M.M., Luo C.S., Clark M.D., Kirk K.A., Kitakaze M., Madden M.C., Cragoe Jr. E.J., and Pohost G.M. NMR measurements of Na+ and cellular energy in ischemic rat heart: role of Na(+)-H+ exchange. Am J Physiol 265 (1993) H2017-H2026
10. Satoh H., Hayashi H., Katoh H., Terada H., and Kobayashi A. Na+/H+ and Na+/Ca2+ exchange in regulation of [Na+]i and [Ca2+]i during metabolic inhibition. Am J Physiol 268 (1995) H1239-H1248
11. Lahorra J.A., Torchiana D.F., Tolis Jr. G., Bashour C.A., Hahn C., Titus J.S., Geffin G.A., and Daggett W.M. Rapid cooling contracture with cold cardioplegia. Ann Thorac Surg 63 (1997) 1353-1360
12. Satoh H., Ginsburg K.S., Qing K., Terada H., Hayashi H., and Bers D.M. KB-R7943 block of Ca(2+) influx via Na(+)/Ca(2+) exchange does not alter twitches or glycoside inotropy but prevents Ca(2+) overload in rat ventricular myocytes. Circulation 101 (2000) 1441-1446
13. Bretschneider H.J., Hubner G., Knoll D., Lohr B., Nordbeck H., and Spieckermann P.G. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino) 16 (1975) 241-260. First paper to describe the first ever cardioplegic solution to be used routinely.
14. Asano M., Inoue K., Ando S., Bito A., Shiojiri Y., Yamada M., and Takaba T. Optimal temperature of continuous lidocaine perfusion for the heart preservation. Jpn J Thorac Cardiovasc Surg 51 (2003) 1-9
15. Dobson G.P., and Jones M.W. Adenosine and lidocaine: a new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J Thorac Cardiovasc Surg 127 (2004) 794-805
16. Yamaguchi S., Watanabe G., Tomita S., and Tabata S. Lidocaine-magnesium blood cardioplegia was equivalent to potassium blood cardioplegia in left ventricular function of canine heart. Interact CardioVasc Thorac Surg 6 (2007) 172-176. The only paper to study the systemic safety aspect of a cardioplegia agent
17. Hearse D.J., O'Brien K., and Braimbridge M.V. Protection of the myocardium during ischemic arrest. Dose-response curves for procaine and lignocaine in cardioplegic solutions. J Thorac Cardiovasc Surg 81 (1981) 873-879
18. +-channel blockade compared hyperkalaemia.
19. Waller E.S. Pharmacokinetic principles of lidocaine dosing in relation to disease state. J Clin Pharmacol 21 (1981) 181-194
20. Foldes F.F., Molloy R., Mc N.P., and Koukal L.R. Comparison of toxicity of intravenously given local anesthetic agents in man. JAMA 172 (1960) 1493-1498
21. Fallouh H.B., and Chambers D.J. ICVTS on-line discussion A The safety of using millimolar doses of lidocaine as cardioplegia. Interact CardioVasc Thorac Surg 6 (2007) 176
22. Cohen N.M., Wise R.M., Wechsler A.S., and Damiano Jr. R.J. Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener. A novel form of myocardial protection?. J Thorac Cardiovasc Surg 106 (1993) 317-328
23. Jayawant A.M., Stephenson Jr. E.R., Matte G.S., Prophet G.A., LaNoue K.F., Griffith J.W., and Damiano Jr. R.J. Potassium-channel opener cardioplegia is superior to St. Thomas' solution in the intact animal. Ann Thorac Surg 68 (1999) 67-74
24. Baczko I., Jones L., McGuigan C.F., Manning Fox J.E., Gandhi M., Giles W.R., Clanachan A.S., and Light P.E. Plasma-membrane KATP channel-mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia. FASEB J 19 (2005) 980-982
25. Walgama O.V., Shattock M.J., and Chambers D.J. Efficacy of a K-ATP channel opener to induce myocardial arrest: species differences. J Mol Cell Cardiol 32 (2000) A40
26. Lawton J.S., Hsia P.W., McClain L.C., Maier G.W., and Damiano Jr. R.J. Myocardial oxygen consumption in the rabbit heart after ischemia: hyperpolarized arrest with pinacidil versus depolarized hyperkalemic arrest. Circulation 96 Suppl. 9 (1997) II-247-II-252
27. Ward J.W., McBurney A., Farrow P.R., and Sharp P. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator. Eur J Clin Pharmacol 26 (1984) 603-608
28. Kowaltowski A.J., Seetharaman S., Paucek P., and Garlid K.D. Bioenergetic consequences of opening the ATP-sensitive K+ channel of heart mitochondria. Am J Physiol Heart Circ Physiol 280 (2001) H649-H657
29. Lawton J.S., Sepic J.D., Allen C.T., Hsia P.W., and Damiano Jr. R.J. Myocardial protection with potassium-channel openers is as effective as St.Thomas' solution in the rabbit heart. Ann Thorac Surg 62 (1996) 31-38 discussion 38-39
30. Belardinelli L., Giles W.R., and West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J Physiol 405 (1988) 615-633
31. Kirsch G.E., Codina J., Birnbaumer L., and Brown A.M. Coupling of ATP-sensitive K+ channels to A1 receptors by G proteins in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 259 (1990) H820-H826
32. Schubert T., Vetter H., Owen P., Reichart B., and Opie L.H. Adenosine cardioplegia. Adenosine versus potassium cardioplegia: effects on cardiac arrest and postischemic recovery in the isolated rat heart. J Thorac Cardiovasc Surg 98 (1989) 1057-1065
33. Jayawant A.M., and Damiano Jr. R.J. The superiority of pinacidil over adenosine cardioplegia in blood-perfused isolated hearts. The Annals of Thoracic Surgery 66 (1998) 1329-1335
34. Mentzer Jr. R.M., Birjiniuk V., Khuri S., Lowe J.E., Rahko P.S., Weisel R.D., Wellons H.A., Barker M.L., and Lasley R.D. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg 229 (1999) 643-649 discussion 649-650
35. Corvera J.S., Kin H., Dobson G.P., Kerendi F., Halkos M.E., Katzmark S., Payne C.S., Zhao Z.Q., Guyton R.A., and Vinten-Johansen J. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J Thorac Cardiovasc Surg 129 (2005) 599-606
36. Jakobsen Ø., Muller S., Aarsæther E., Steensrud T., and Sørlie D.G. Adenosine instead of supranormal potassium in cardioplegic solution improves cardioprotection. Eur J Cardiothorac Surg 32 (2007) 493-500
37. Bretschneider H.J. Survival Time and Recuperative Time of the Heart in Normothermia and Hypothermia. Verh Dtsch Ges Kreislaufforsch 30 (1964) 11-34
38. Bers D.M. Cardiac excitation-contraction coupling. Nature 415 (2002) 198-205
39. Chapman R.A., and Tunstall J. The calcium paradox of the heart. Prog Biophys Mol Biol 50 (1987) 67-96
40. Jynge P., Hearse D.J., and Braimbridge M.V. Protection of the ischemic myocardium. Volume-duration relationships and the efficacy of myocardial infusates. J Thorac Cardiovasc Surg 76 (1978) 698-705
41. Vouhe P.R., Helias J., and Grondin C.M. Myocardial protection through cold cardioplegia using diltiazem, a calcium channel blocker. Ann Thorac Surg 30 (1980) 342-348
42. Yamamoto F., Manning A.S., Braimbridge M.V., and Hearse D.J. Cardioplegia and slow calcium-channel blockers. Studies with verapamil. J Thorac Cardiovasc Surg 86 (1983) 252-261
43. Popovic J., Mitic R., Sabo A., Mikov M., Jakovljevic V., and Dakovic-Svajcer K. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. Eur J Drug Metab Pharmacokinet 31 (2006) 87-96
44. Dillon J.S., and Nayler W.G. [3H]-verapamil binding to rat cardiac sarcolemmal membrane fragments; an effect of ischaemia. Br J Pharmacol 90 (1987) 99-109
45. Shattock M.J., Hearse D.J., and Fry C.H. The ionic basis of the anti-ischemic and anti-arrhythmic properties of magnesium in the heart. J Am Coll Nutr 6 (1987) 27-33
46. Maruyama Y., and Chambers D.J. Myocardial protection: efficacy of a novel magnesium-based cardioplegia (RS-C) compared to St Thomas' Hospital cardioplegic solution. Interact CardioVasc Thorac Surg 7 (2008) 745-749
47. Hearse D.J., Stewart D.A., and Braimbridge M.V. Myocardial protection during ischemic cardiac arrest. The importance of magnesium in cardioplegic infusates. J Thorac Cardiovasc Surg 75 (1978) 877-885
48. Vahl C.F., Bonz A., Hagl C., Timek T., Herold U., Fuchs H., Kochsiek N., and Hagl S. Cardioplegia on the contractile apparatus level: evaluation of a new concept for myocardial preservation in perfused pig hearts. Thorac Cardiovasc Surg 43 (1995) 185-193
49. Mulieri L.A., Hasenfuss G., Ittleman F., Blanchard E.M., and Alpert N.R. Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. Circ Res 65 (1989) 1441-1449
50. Gwathmey J.K., Hajjar R.J., and Solaro R.J. Contractile deactivation and uncoupling of crossbridges. Effects of 2,3-butanedione monoxime on mammalian myocardium. Circ Res 69 (1991) 1280-1292
51. Jayawant A.M., Stephenson Jr. E.R., and Damiano Jr. R.J. 2,3-Butanedione monoxime cardioplegia: advantages over hyperkalemia in blood-perfused isolated hearts. Ann Thorac Surg 67 (1999) 618-623
52. Snabaitis A.K., and Chambers D.J. Long-term myocardial preservation: beneficial and additive effects of polarized arrest (Na+-channel blockade), Na+/H+-exchange inhibition, and Na+/K+/2Cl- -cotransport inhibition combined with calcium desensitization. Transplantation 68 (1999) 1444-1453
53. Hohnloser S.H., Meinertz T., Klingenheben T., Sydow B., and Just H. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group. Am J Cardiol 67 (1991) 1319-1323
54. Roth E., and Torok B. Effect of the ultrashort-acting beta-blocker Brevibloc on free-radical-mediated injuries during the early reperfusion state. Basic Res Cardiol 86 (1991) 422-433
55. Roth E., Matos G., Guarnieri C., Papp B., and Varga J. Influence of the beta-blocker therapy on neutrophil superoxide generation and platelet aggregation in experimental myocardial ischemia and reflow. Acta Physiol Hung 83 (1995) 163-170
56. Boldt J., Brosch C., Lehmann A., Suttner S., and Isgro F. The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients. Anesth Analg 99 (2004) 1009-1017
57. Geissler H.J., Davis K.L., Laine G.A., Ostrin E.J., Mehlhorn U., Hekmat K., Warters R.D., and Allen S.J. Myocardial protection with high-dose beta-blockade in acute myocardial ischemia. Eur J Cardiothorac Surg 17 (2000) 63-70
58. Booth J.V., Spahn D.R., McRae R.L., Chesnut L.C., El-Moalem H., Atwell D.M., Leone B.J., and Schwinn D.A. Esmolol improves left ventricular function via enhanced beta-adrenergic receptor signaling in a canine model of coronary revascularization. Anesthesiology 97 (2002) 162-169
59. Kuhn-Regnier F., Geissler H.J., Marohl S., Mehlhorn U., and De Vivie E.R. Beta-blockade in 200 coronary bypass grafting procedures. Thorac Cardiovasc Surg 50 (2002) 164-167
60. Mehlhorn U., Sauer H., Kuhn-Regnier F., Sudkamp M., Dhein S., Eberhardt F., Grond S., Horst M., Hekmat K., Geissler H.J., Warters R.D., et al. Myocardial beta-blockade as an alternative to cardioplegic arrest during coronary artery surgery. Cardiovasc Surg 7 (1999) 549-557
61. Kuhn-Regnier F., Natour E., Dhein S., Dapunt O., Geissler H.J., LaRose K., Gorg C., and Mehlhorn U. Beta-blockade versus Buckberg blood-cardioplegia in coronary bypass operation. Eur J Cardiothorac Surg 15 (1999) 67-74
62. Bessho R., and Chambers D.J. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent. J Thorac Cardiovasc Surg 122 (2001) 993-1003
63. Bessho R., and Chambers D.J. Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia. J Thorac Cardiovasc Surg 124 (2002) 340-351
64. Arlock P., Wohlfart B., Sjoberg T., and Steen S. The negative inotropic effect of esmolol on isolated cardiac muscle. Scand Cardiovasc J 39 (2005) 250-254
65. Fallouh H.B., McLatchie L.M., Shattock M.J., Chambers D.J., and Kentish J.C. Abstract 1556: esmolol as a cardioplegic agent; an effect beyond {beta}-blockade. Circulation 116 (2007) II_323-II_324 16_MeetingAbstracts
66. Deng C.Y., Lin S.G., Zhang W.C., Kuang S.J., Qian W.M., Wu S.L., Shan Z.X., Yang M., and Yu X.Y. Esmolol inhibits Na+ current in rat ventricular myocytes. Methods Find Exp Clin Pharmacol 28 (2006) 697-702
67. Erhardt P.W., Woo C.M., Matier W.L., Gorczynski R.J., and Anderson W.G. Ultra-short-acting beta-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function. J Med Chem 26 (1983) 1109-1112
68. Pirk J., Kolar F., Ost'adal B., Sedivy J., Stambergova A., and Kellovsky P. The effect of the ultrashort beta-blocker esmolol on cardiac function recovery: an experimental study. Eur J Cardiothorac Surg 15 (1999) 199-203